ZA200805247B - Quinazoline derivatives, process for their preparation and their use as anti-cancer agents - Google Patents

Quinazoline derivatives, process for their preparation and their use as anti-cancer agents

Info

Publication number
ZA200805247B
ZA200805247B ZA200805247A ZA200805247A ZA200805247B ZA 200805247 B ZA200805247 B ZA 200805247B ZA 200805247 A ZA200805247 A ZA 200805247A ZA 200805247 A ZA200805247 A ZA 200805247A ZA 200805247 B ZA200805247 B ZA 200805247B
Authority
ZA
South Africa
Prior art keywords
preparation
cancer agents
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
ZA200805247A
Other languages
English (en)
Inventor
Brian Aquila
Jayachandran Ezhuthachan
Paul Lyne
Timothy Pontz
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200805247B publication Critical patent/ZA200805247B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200805247A 2005-12-22 2008-06-17 Quinazoline derivatives, process for their preparation and their use as anti-cancer agents ZA200805247B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75331305P 2005-12-22 2005-12-22

Publications (1)

Publication Number Publication Date
ZA200805247B true ZA200805247B (en) 2010-02-24

Family

ID=37846121

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805247A ZA200805247B (en) 2005-12-22 2008-06-17 Quinazoline derivatives, process for their preparation and their use as anti-cancer agents

Country Status (12)

Country Link
US (1) US20080306096A1 (xx)
EP (1) EP1966159A2 (xx)
JP (1) JP2009520784A (xx)
KR (1) KR20080079673A (xx)
CN (1) CN101341133A (xx)
AU (1) AU2006328194A1 (xx)
BR (1) BRPI0620462A2 (xx)
CA (1) CA2632929A1 (xx)
IL (1) IL192009A0 (xx)
NO (1) NO20082709L (xx)
WO (1) WO2007071963A2 (xx)
ZA (1) ZA200805247B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CA2716951A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP2268623B9 (en) 2008-03-17 2018-02-28 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
ES2915065T3 (es) 2008-07-31 2022-06-20 Firmenich Incorporated Procedimientos para hacer potenciadores del sabor dulce
EP2398797B1 (en) * 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
CA2784807C (en) * 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CA2865043A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
WO2014025706A1 (en) 2012-08-06 2014-02-13 Senomyx, Inc. Sweet flavor modifier
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
CN103288760B (zh) * 2013-05-16 2015-02-18 苏州明锐医药科技有限公司 卡奈替尼的制备方法
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
US11945813B2 (en) 2018-08-07 2024-04-02 Firmenich Incorporated 5-substituted 4-amino-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021247845A1 (en) * 2020-06-05 2021-12-09 Dana-Farber Cancer Institute, Inc. Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
CN112028886B (zh) * 2020-09-10 2021-07-06 四川大学华西医院 一种靶向egfr的荧光分子探针及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
JP2002526538A (ja) * 1998-10-01 2002-08-20 アストラゼネカ アクチボラグ 化学化合物
ES2336094T3 (es) * 2002-03-29 2010-04-08 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de quinasa raf.
BRPI0512075A (pt) * 2004-06-15 2008-02-06 Astrazeneca Ab composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
NZ553087A (en) * 2004-08-31 2010-12-24 Astrazeneca Ab Quinazolinone derivatives and their use as B-raf inhibitors
US20090170849A1 (en) * 2006-04-05 2009-07-02 Astrazeneca Ab Quinazolinone derivatives having b-raf inhibitory activity

Also Published As

Publication number Publication date
NO20082709L (no) 2008-08-13
JP2009520784A (ja) 2009-05-28
EP1966159A2 (en) 2008-09-10
CA2632929A1 (en) 2007-06-28
IL192009A0 (en) 2008-12-29
AU2006328194A1 (en) 2007-06-28
CN101341133A (zh) 2009-01-07
WO2007071963A3 (en) 2007-08-09
BRPI0620462A2 (pt) 2011-11-16
KR20080079673A (ko) 2008-09-01
WO2007071963A2 (en) 2007-06-28
US20080306096A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
IL192009A0 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
EP1990337A4 (en) CHINAZOLINE DERIVATIVES, METHOD OF MANUFACTURE AND USES THEREOF
ZA200903160B (en) Sulfonyl-Phenyl-2H-[1,2,4]Oxodiazol-5-one Derivatives, Processes for their preparation and their use as pharmaceuticals
IL194835A (en) History of cyclohexylpyrazole-lactam, an intermediate substance for their use in the preparation of drugs
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
ZA200805939B (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
EP1937766A4 (en) MODIFIED POLYAMIDES, USES THEREOF AND MANUFACTURING METHOD THEREFOR
IL203206A (en) 2-Amino Derivatives, 4-Amido Quinazoline, Drugs Containing and Using Theirs, and Process for Manufacturing
PT1922309E (pt) Derivados de n-fenil-2-pirimidina-amina e processo para a sua preparação
HUP0500920A2 (en) Oxadiazole derivatives, process for their preparation and their use
IL187235A0 (en) 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
IL193339A0 (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL193341A0 (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
PL1874765T3 (pl) Pochodne mocznika, sposoby ich otrzymywania i zastosowanie
EP1961753A4 (en) DERIVATIVES OF PIRAZOLOPYRIMIDINONE, THEIR PREPARATION AND USE
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
HUP0500921A2 (en) Tetrazole derivatives, process for their preparation and their use
ZA200808754B (en) Tetrahydronaphthaline derivatives, methods for the production and use hereof as anti-inflammatory agents
EP2292234A4 (en) COMPOSITION CONTAINING QUINAZOLINE DERIVATIVES, PROCESS FOR PREPARING SAME AND APPLICATIONS THEREOF.
GB0504018D0 (en) Quinazoline derivatives
IL193384A0 (en) Substituted prolinamides, their preparation and their use as pharmaceuticals
ZA200803445B (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
IL190596A0 (en) 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
IL190230A0 (en) Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
IL190334A0 (en) Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents